Asset profile
mitomycin · UroGen Pharma (URGN)
- Indication
- pyelocalyceal solution
- Also known as
- Jelmyto
Company
URGNUroGen Pharma
URGNUroGen PharmaUroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by …
On the calendar
Timeline
Newest first.
May 8, 2025
12:00 AM
URGNUroGen PharmaRegistered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT07566156 | Phase 3 | Recruiting | Mar 31, 2030 | 390 | 21 of 29 sites in the United States |
| NCT02299999 | Phase 2 | Active, not recruiting | Dec 1, 2022 | 1460 | 0 of 25 sites in the United States |
| NCT02092298 | Phase 2 | Completed | May 12, 2020 | 21 | 1 of 1 sites in the United States |
| NCT07271355 | Phase 3 | Recruiting | Feb 28, 2031 | 129 | 5 of 5 sites in the United States |
| NCT06770582 | Phase 2 | Recruiting | Feb 1, 2032 | 160 | 145 of 147 sites in the United States |
| NCT06211764 | Phase 3 | Active, not recruiting | Nov 27, 2030 | 272 | 29 of 123 sites in the United States |
| NCT01004978 | Phase 3 | Completed | Feb 11, 2021 | 235 | 281 of 281 sites in the United States |
| NCT06822010 | Phase 2 | Recruiting | Apr 1, 2028 | 28 | 1 of 1 sites in the United States |
| NCT00005825 | Phase 2 | Unknown | 1 of 1 sites in the United States |
More from UroGen Pharma
Other drugs and candidates from the same company tracked in this sector.